Chinook Therapeutics, Inc. (KDNY): Price and Financial Metrics
KDNY Price/Volume Stats
|Current price||$40.39||52-week high||$40.51|
|Prev. close||$40.30||52-week low||$18.34|
|Day high||$40.51||Avg. volume||1,186,257|
|50-day MA||$36.70||Dividend yield||N/A|
|200-day MA||$26.37||Market Cap||2.90B|
KDNY Stock Price Chart Interactive Chart >
Chinook Therapeutics, Inc. (KDNY) Company Bio
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates include BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook Therapeutics, Inc. is based in Seattle, Washington.
KDNY Latest News Stream
|Loading, please wait...|
KDNY Latest Social Stream
View Full KDNY Social Stream
Latest KDNY News From Around the Web
Below are the latest news stories about CHINOOK THERAPEUTICS INC that investors may wish to consider to help them evaluate KDNY as an investment opportunity.
Chinook Therapeutics Presents Data from CHK-336 Phase 1 Trial in Healthy Volunteers and New Insights into the Role of Failed Repair in Chronic Kidney Disease at the 60th European Renal Association (ERA) Congress
CHK-336 was generally well tolerated in healthy volunteers (HV) who received single doses up to 500 mg and multiple doses up to 60 mg for 14 daysPharmacokinetics (PK) was well characterized with dose-proportional exposures and a half-life that supports once-daily dosingSuccessful implementation of a novel 13C2-glycolate tracer established proof-of-mechanism of CHK-336 to block hepatic oxalate production in HVsOne serious adverse event (SAE) of anaphylaxis occurred in a multiple ascending dose HV
Stocks are modestly higher this afternoon amid hopes of a dovish Fed, with the central bank's policy decision due out Wednesday.
We're starting off the week with a breakdown of the biggest pre-market stock movers traders need to know about for Monday morning!
Chinook Therapeutics (KDNY) stock is rocketing higher on Monday after the company announced it's being acquired by Novartis AG (NVS).
Oncorus (ONCR) stock is taking a beating on Monday after revealing plans for a vote during an upcoming special shareholder meeting.
KDNY Price Returns